148 related articles for article (PubMed ID: 12888931)
1. The blood coagulation mechanism in multiple myeloma.
Zangari M; Saghafifar F; Mehta P; Barlogie B; Fink L; Tricot G
Semin Thromb Hemost; 2003 Jun; 29(3):275-82. PubMed ID: 12888931
[TBL] [Abstract][Full Text] [Related]
2. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
[TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
Elice F; Fink L; Tricot G; Barlogie B; Zangari M
Br J Haematol; 2006 Aug; 134(4):399-405. PubMed ID: 16882132
[TBL] [Abstract][Full Text] [Related]
4. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor.
Negaard HF; Iversen PO; Østenstad B; Iversen N; Holme PA; Sandset PM
Thromb Haemost; 2008 Jun; 99(6):1040-8. PubMed ID: 18521506
[TBL] [Abstract][Full Text] [Related]
5. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Zangari M; Saghafifar F; Anaissie E; Badros A; Desikan R; Fassas A; Mehta P; Morris C; Toor A; Whitfield D; Siegel E; Barlogie B; Fink L; Tricot G
Blood Coagul Fibrinolysis; 2002 Apr; 13(3):187-92. PubMed ID: 11943931
[TBL] [Abstract][Full Text] [Related]
6. Congenital and acquired activated protein C resistance.
Nicolaes GA; Dahlbäck B
Semin Vasc Med; 2003 Feb; 3(1):33-46. PubMed ID: 15199491
[TBL] [Abstract][Full Text] [Related]
7. Overview of the postulated mechanisms linking cancer and thrombosis.
ten Cate H; Falanga A
Pathophysiol Haemost Thromb; 2008; 36(3-4):122-30. PubMed ID: 19176985
[TBL] [Abstract][Full Text] [Related]
8. [National evaluation of the diagnosis of activated protein C resistance].
Montiel-Manzano G; de la Peña-Díaz A; Majluf-Cruz A; Cesarman-Maus G; Corona-de la Peña N; Cruz-Cruz D; Gaminio E; Martínez-Murillo C; Mayagoitia T; Miranda-Peralta E; Poblete T; Quintana-Martínez S; Ramírez R; Razo D; Ruiz de Chávez-Ochoa A; Reyes-Núñez VA; Salazar R; Vicencio-Santiago GV; Villa R
Rev Invest Clin; 2003; 55(3):358-69. PubMed ID: 14515684
[TBL] [Abstract][Full Text] [Related]
9. Thrombosis in multiple myeloma.
Zangari M; Elice F; Fink L; Tricot G
Expert Rev Anticancer Ther; 2007 Mar; 7(3):307-15. PubMed ID: 17338651
[TBL] [Abstract][Full Text] [Related]
10. Thrombophilia in cancer.
Falanga A
Semin Thromb Hemost; 2005 Feb; 31(1):104-10. PubMed ID: 15706482
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis of thrombophilia based on coagulation and genetic studies].
Bałszan-Kowalska I
Ann Acad Med Stetin; 2002; 48():179-93. PubMed ID: 14601477
[TBL] [Abstract][Full Text] [Related]
12. Thrombophilia and activated protein C resistance.
Selzman CH; Whitehill TA; Krupski WC
Ann Vasc Surg; 1998 Nov; 12(6):601-4. PubMed ID: 9841693
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of the thrombophilic state in the cancer patient.
Falanga A; Rickles FR
Semin Thromb Hemost; 1999; 25(2):173-82. PubMed ID: 10357085
[TBL] [Abstract][Full Text] [Related]
14. Thrombophilias and recurrent pregnancy loss.
Kutteh WH; Triplett DA
Semin Reprod Med; 2006 Feb; 24(1):54-66. PubMed ID: 16418978
[TBL] [Abstract][Full Text] [Related]
15. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression.
Falanga A; Marchetti M; Vignoli A; Balducci D
Clin Adv Hematol Oncol; 2003 Nov; 1(11):673-8. PubMed ID: 16258469
[TBL] [Abstract][Full Text] [Related]
16. [Platelets haemostatic in patients with multiple myeloma].
Kamińska J; Mantur M; Sawicka-Powierza J
Pol Merkur Lekarski; 2009 Nov; 27(161):404-7. PubMed ID: 19999806
[TBL] [Abstract][Full Text] [Related]
17. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies.
Falanga A; Barbui T; Rickles FR
Semin Thromb Hemost; 2008 Mar; 34(2):204-10. PubMed ID: 18645927
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.
van Marion AM; Auwerda JJ; Lisman T; Sonneveld P; de Maat MP; Lokhorst HM; Leebeek FW
Leuk Res; 2008 Jul; 32(7):1078-84. PubMed ID: 18241919
[TBL] [Abstract][Full Text] [Related]
19. Activated protein C resistance due to factor V Leiden, elevated coagulation factor VIII and postoperative deep vein thrombosis in late breast reconstruction with a free TRAM flap: a report of two cases.
Olsson E; Höijer P
Br J Plast Surg; 2005 Jul; 58(5):720-3. PubMed ID: 15992531
[TBL] [Abstract][Full Text] [Related]
20. Laboratory evaluation of hypercoagulability.
Khor B; Van Cott EM
Clin Lab Med; 2009 Jun; 29(2):339-66. PubMed ID: 19665682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
